Lipids Alterations Associated with Metformin in Healthy Subjects: An Investigation Using Mass Spectrometry Shotgun Approach
Open Access
- 29 September 2022
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (19) , 11478
Abstract
Metformin is an orally effective insulin-sensitizing drug widely prescribed for treating type 2 diabetes mellitus (T2DM). Metformin has been reported to alter lipid metabolism. However, the molecular mechanisms behind its impact on lipid metabolism remain partially explored and understood. In the current study, mass spectrometry-based lipid profiling was used to investigate the lipidomic changes in the serum of 26 healthy individuals after a single-dose intake of metformin. Samples were analyzed at five-time points: preadministration, before the maximum concentration of metformin (Cmax), Cmax, after Cmax, and 36 h post-administration. A total of 762 molecules were significantly altered between the five-time points. Based on a comparison between baseline level and Cmax, metformin significantly increased and decreased the level of 33 and 192 lipids, respectively (FDR ≤ 0.05 and fold change cutoff of 1.5). The altered lipids are mainly involved in arachidonic acid metabolism, steroid hormone biosynthesis, and glycerophospholipid metabolism. Furthermore, several lipids acted in an opposed or similar manner to metformin levels and included fatty acyls, sterol lipids, glycerolipids, and glycerophospholipids. The significantly altered lipid species pointed to fundamental lipid signaling pathways that could be linked to the pleiotropic effects of metformin in T2DM, insulin resistance, polycystic ovary syndrome, cancer, and cardiovascular diseases.Keywords
Funding Information
- University Diabetes Center, King Saud University
This publication has 74 references indexed in Scilit:
- Metformin: an old but still the best treatment for type 2 diabetesDiabetology & Metabolic Syndrome, 2013
- Effectiveness of Metformin on Weight Loss in Non-Diabetic Individuals with ObesityExperimental and Clinical Endocrinology & Diabetes, 2012
- Glycerolipid/free fatty acid cycle and islet β-cell function in health, obesity and diabetesMolecular and Cellular Endocrinology, 2012
- Cellular and molecular mechanisms of metformin: an overviewClinical Science, 2011
- Metformin selectively attenuates mitochondrial H2O2 emission without affecting respiratory capacity in skeletal muscle of obese ratsFree Radical Biology and Medicine, 2010
- Eicosanoids and cancerNature Reviews Cancer, 2010
- AMPK: An Emerging Drug Target for Diabetes and the Metabolic SyndromeCell Metabolism, 2009
- PGF2α-associated vascular smooth muscle hypertrophy is ROS dependent and involves the activation of mTOR, p70S6k, and PTENProstaglandins & Other Lipid Mediators, 2008
- Metformin for the treatment of polycystic ovary syndromeObstetrics & Gynecology, 2003
- Thromboxane Biosynthesis and Platelet Function in Type II Diabetes MellitusNew England Journal of Medicine, 1990